Thiamine
| Evidence Level: L5 | Predicted Indications: 4 |
Table of Contents
Thiamine: From Thiamine Deficiency to Hyperthyroidism
One-Sentence Summary
Thiamine (Vitamin B1) is classically used to treat thiamine deficiency states such as beriberi and Wernicke’s encephalopathy. The TxGNN model predicts it may be effective for Hyperthyroidism-associated thiamine deficiency and its cardiovascular/neurological complications, with 1 clinical trial and 20 publications currently supporting this direction — though most evidence is at the case-report level.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Thiamine (Vitamin B1) deficiency states, e.g., beriberi and Wernicke’s encephalopathy (no India-specific labeled indication text available — see data gaps below) |
| Predicted New Indication | Hyperthyroidism |
| TxGNN Prediction Score | 99.44% |
| Evidence Level | L3 (one completed observational/pilot study, remainder case reports and old mechanistic studies) |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, Thiamine is an essential water-soluble vitamin that, as thiamine pyrophosphate, serves as a cofactor for key enzymes in carbohydrate metabolism (pyruvate dehydrogenase, transketolase) and is critical for normal neuronal and cardiac function. Its efficacy in correcting thiamine deficiency states has been well established for over a century.
The mechanistic link to hyperthyroidism stems from the hypermetabolic state that thyrotoxicosis induces: increased basal metabolic rate raises tissue demand for thiamine as a metabolic cofactor, which can precipitate a relative or absolute thiamine deficiency even without classic malnutrition. This has been documented to manifest as high-output cardiac failure (“thyrotoxic beriberi”) and, in severe cases, Wernicke’s encephalopathy — particularly in the setting of hyperemesis gravidarum with coexisting gestational thyrotoxicosis.
Because the underlying biochemical vulnerability (accelerated thiamine turnover) is a direct consequence of the hyperthyroid state itself, prophylactic or therapeutic thiamine supplementation in hyperthyroid patients is mechanistically plausible as a supportive measure to prevent or treat these deficiency-related complications, rather than as a treatment for hyperthyroidism per se.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT02767245 | NA (pilot) | Completed | 12 | Pilot study evaluating prevalence of thiamine deficiency and cardiovascular function improvement after thiamine supplementation in patients with severe hyperthyroidism |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 26567494 | 2015 | Review | Crit Care Nurs Clin North Am | Reviews thyrotoxicosis and beriberi as causes of high-output heart failure |
| 32983708 | 2020 | Case Report | Cureus | Wernicke’s encephalopathy associated with transient gestational hyperthyroidism and hyperemesis gravidarum |
| 18026802 | 2008 | Case Report | J Gen Intern Med | Thyrotoxicosis-associated Wernicke’s encephalopathy from thiamine deficiency |
| 25148818 | 2014 | Case Report | Endocr Pract | Gestational thyrotoxicosis with hyperemesis gravidarum leading to Wernicke’s encephalopathy |
| 22436368 | 2013 | Case Report | Neurologia (Barcelona) | Wernicke’s encephalopathy secondary to hyperthyroidism and thiaminase-rich food ingestion |
| 36176825 | 2022 | Case Report | Cureus | Uncommon presentation of hyperthyroidism culminating in neurological (Wernicke’s) complications |
| 34017792 | 2021 | Case Report | J Family Med Prim Care | Seizure as presenting sign of Wernicke’s encephalopathy induced by hyperemesis gravidarum with thyrotoxicosis |
| 34995426 | 2021 | Case Report | S D Med | Visual disturbances from Wernicke’s encephalopathy in a Graves’ disease patient |
| 36593922 | 2023 | Case Report | Radiol Case Rep | Uncommon presentation of Wernicke-Korsakoff syndrome in a pregnant patient with pre-gestational hyperthyroidism |
| 7416185 | 1980 | Case Series | Am J Med | 23-case series of beriberi heart disease in Japan, discussing thiamine deficiency mechanisms relevant to hypermetabolic states |
India Market Information
Thiamine currently holds no marketing authorization on file for the India market (0 registrations, market status: Not Marketed). No product-level licensing data is available to populate an authorization table.
Safety Considerations
Please refer to the package insert for safety information. No structured warnings, contraindications, or drug interaction data were available in the current evidence pack (all fields marked as data gaps).
Known data gap: Detailed regulatory-agency labeled warnings/contraindications (blocking severity) have not yet been sourced, which prevents completion of an initial (S1) safety screening for this candidate.
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanistic rationale (accelerated thiamine turnover in the hypermetabolic hyperthyroid state) is plausible and supported by a body of case reports and one small completed pilot trial (n=12), but there are no randomized controlled trials, and the drug is not currently registered in the India market. A blocking-severity data gap on official safety labeling also prevents completion of the required initial safety screening.
To proceed, the following is needed:
- Official regulatory-agency product label (warnings, contraindications) to complete S1 safety screening (currently blocking)
- Confirmed mechanism-of-action documentation from DrugBank or equivalent source
- Larger controlled studies evaluating thiamine supplementation outcomes specifically in hyperthyroid/thyrotoxic patients (current evidence base is dominated by case reports)
- Confirmation of local marketing/registration status if India launch is being considered
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.